Prot#1245.110: EMPORER - A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF)

Project: Research project

Project Details

StatusFinished
Effective start/end date11/30/18 → 11/30/21

Funding

  • Quintiles, Inc. (Prot# 1245.110 // Prot# 1245.110)
  • Boehringer Ingelheim Pharmaceuticals, Inc. (Prot# 1245.110 // Prot# 1245.110)